Regentis Biomaterials Ltd. RGNT
1.98
(0.06)
(2.94%)
as of 25 Sep
- Market cap
- $15.8M
- P/E
- —
Follow RGNT
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+1 more TTM period Free account |
|
| 0.00% | — | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | — | — | |
Free Cash Flow |
(5.20) | (3.58) | — | — | |
Capital Expenditures |
(0.03) | — | — | — | |
Piotroski F-Score |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Cash ROIC |
(31.04%) | (26.85%) | 0.00% | 0.00% | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | — | — | |
Depreciation/Fixed assets |
0.16 | — | — | — | |
Capex/Depreciation |
(6.60) | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | — | — | |
Capex per Share |
0.00 | — | — | — | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates